BioMarin CAO Andrea Acosta resigns; CFO Mueller to serve as interim principal accounting officer

BIOMARIN PHARMACEUTICAL INC

Andrea Acosta, Group VP and CAO, resigns effective Jan 28, 2022 to pursue another career opportunity.
Company will search for a successor; if none appointed by Jan 28, CFO Brian Mueller will serve as principal accounting officer.
Mueller will continue as CFO with no adjustment to compensation for additional duties.
Mueller's bio previously disclosed in 2021 proxy; no related party transactions reported.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Andrea Acosta

Group Vice President, Chief Accounting Officer, and principal accounting officer

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2022-01-28
Successor: Brian Mueller
Filed: November 3, 2021, 7:59 PM ET

On October 29, 2021, Andrea Acosta, the Group Vice President, Chief Accounting Officer, and principal accounting officer of BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) notified BioMarin of her decision to resign, effective as of January 28, 2022 (the “Effective Date”), in order to pursue another career opportunity.

Appointed (interim)

Brian Mueller

principal accounting officer

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2022-01-28
Filed: November 3, 2021, 7:59 PM ET

In the event that the Company has not appointed a successor on or prior to the Effective Date, Brian Mueller, BioMarin’s Executive Vice President, Finance and Chief Financial Officer, will serve as the Company’s principal accounting officer from the Effective Date until Ms. Acosta’s successor is appointed.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrea Acosta resigned as Group Vice President, Chief Accounting Officer, and principal accounting officer at BIOMARIN PHARMACEUTICAL INC.

Action: resigned
Role: Group Vice President, Chief Accounting Officer, and principal accounting officer

Exact text from the filing

On October 29, 2021, Andrea Acosta, the Group Vice President, Chief Accounting Officer, and principal accounting officer of BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) notified BioMarin of her decision to resign, effective as of January 28, 2022 (the “Effective Date”), in order to pursue another career opportunity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Mueller was appointed as principal accounting officer at BIOMARIN PHARMACEUTICAL INC.

Action: appointed
Role: principal accounting officer

Exact text from the filing

In the event that the Company has not appointed a successor on or prior to the Effective Date, Brian Mueller, BioMarin’s Executive Vice President, Finance and Chief Financial Officer, will serve as the Company’s principal accounting officer from the Effective Date until Ms. Acosta’s successor is appointed.

View on SEC.gov

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-21-318400

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.